JP2004536615A5 - - Google Patents

Download PDF

Info

Publication number
JP2004536615A5
JP2004536615A5 JP2003517263A JP2003517263A JP2004536615A5 JP 2004536615 A5 JP2004536615 A5 JP 2004536615A5 JP 2003517263 A JP2003517263 A JP 2003517263A JP 2003517263 A JP2003517263 A JP 2003517263A JP 2004536615 A5 JP2004536615 A5 JP 2004536615A5
Authority
JP
Japan
Prior art keywords
cells
cell
vaccine
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003517263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536615A (ja
Filing date
Publication date
Priority claimed from PCT/IT2001/000419 external-priority patent/WO2003012085A1/en
Application filed filed Critical
Publication of JP2004536615A publication Critical patent/JP2004536615A/ja
Publication of JP2004536615A5 publication Critical patent/JP2004536615A5/ja
Pending legal-status Critical Current

Links

JP2003517263A 2001-07-30 2002-07-25 抗原提示細胞、その調製方法およびその癌ワクチンのための使用 Pending JP2004536615A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IT2001/000419 WO2003012085A1 (en) 2001-07-30 2001-07-30 Antigen presenting cells, method for their preparation and their use for cancer vaccines
PCT/IT2002/000488 WO2003012086A1 (en) 2001-07-30 2002-07-25 Antigen presenting cells, method for their preparation and their use for cancer vaccines

Publications (2)

Publication Number Publication Date
JP2004536615A JP2004536615A (ja) 2004-12-09
JP2004536615A5 true JP2004536615A5 (enExample) 2006-01-05

Family

ID=11133712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003517263A Pending JP2004536615A (ja) 2001-07-30 2002-07-25 抗原提示細胞、その調製方法およびその癌ワクチンのための使用

Country Status (16)

Country Link
US (3) US20030119187A1 (enExample)
EP (1) EP1412485B1 (enExample)
JP (1) JP2004536615A (enExample)
KR (1) KR100916670B1 (enExample)
CN (1) CN100591762C (enExample)
AT (1) ATE505533T1 (enExample)
AU (1) AU2002334387B2 (enExample)
BR (1) BR0211520A (enExample)
CA (1) CA2453522C (enExample)
DE (1) DE60239741D1 (enExample)
DK (1) DK1412485T3 (enExample)
ES (1) ES2367256T3 (enExample)
HU (1) HUP0401753A3 (enExample)
MX (1) MXPA04000885A (enExample)
PL (1) PL211907B1 (enExample)
WO (2) WO2003012085A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
PT1592441E (pt) * 2003-02-06 2012-05-21 Aduro Biotech Listeria atenuada relativamente à entrada em células não patogénicas, vacinas compreendendo a listeria e métodos para sua utilização
WO2004084936A2 (en) * 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
DE10329240A1 (de) * 2003-06-24 2005-01-20 Epigenomics Ag Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
ES2390967T3 (es) * 2004-01-20 2012-11-20 Aichi Prefecture Epítopo/péptido reconocido por LTC específico para Ep-CAM con restricción por ALH-A2402 y su utilización
WO2005075646A1 (ja) * 2004-02-03 2005-08-18 Kurume University ストレス誘導抗アポトーシス分子(iex−1)由来ペプチド
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007011693A2 (en) 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
GB0700058D0 (en) * 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
JP2013512694A (ja) * 2009-12-08 2013-04-18 ウィルソン ウォルフ マニュファクチャリング コーポレイション 養子細胞療法のための細胞を培養する方法
PL2729008T3 (pl) * 2011-07-07 2017-10-31 Res Cancer Institute Of America Systemy, sposoby i formulacje do leczenia raka
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
BR112014004779B1 (pt) 2011-08-30 2022-01-18 Astex Pharmaceuticals, Inc Formulações de derivados de decitabina, kit e processos relacionados
EP3662911A1 (en) * 2012-10-30 2020-06-10 MEI Pharma, Inc. Combination of azacitidine and pracinostat to treat myelodysplastic syndrome (mds)
US9562219B2 (en) * 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
CA2986687A1 (en) * 2015-05-22 2016-12-01 Brian J. Czerniecki Manufacturing multi-dose injection ready dendritic cell vaccines
MX2018000016A (es) 2015-07-02 2019-01-31 Otsuka Pharma Co Ltd Composiciones farmaceuticas liofilizadas.
CN105132371B (zh) * 2015-07-24 2016-05-25 北京鼎成肽源生物技术有限公司 体外提呈、激活dc细胞的方法及其应用
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US11369585B2 (en) 2017-03-17 2022-06-28 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.
CN107557333B (zh) * 2017-10-16 2018-07-31 北京鼎成肽源生物技术有限公司 一种用于细胞治疗的新抗原呈递细胞的制备方法
EP3710434A4 (en) 2017-11-17 2021-07-28 Research Cancer Institute of America COMPOSITIONS, METHODS, SYSTEMS AND / OR KITS FOR THE PREVENTION AND / OR TREATMENT OF NEOPLASMS
KR102319259B1 (ko) 2019-07-26 2021-10-28 정재웅 지반천공기용 확장리더 안전제어장치
WO2021027057A1 (zh) * 2019-08-15 2021-02-18 成都冕康生物科技有限公司 一种针对ebv病毒抗原的b细胞疫苗及其制备方法
CN114099655A (zh) * 2021-11-16 2022-03-01 苏州大学 一种预防或治疗癌症的疫苗系统及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0817854A2 (en) * 1995-03-31 1998-01-14 Wolf, Hans, Prof. Dr. Antigen presentation system based on retrovirus-like particles
ES2279580T3 (es) * 1997-09-15 2007-08-16 Genetic Immunity, Llc Composiciones para administrar genes a celulas de la piel que presentan antigenos.
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines

Similar Documents

Publication Publication Date Title
JP2004536615A5 (enExample)
US12227764B2 (en) Pepmixes to generate multiviral CTLs with broad specificity
CN100591762C (zh) 抗原呈递细胞、其制备方法及其用于癌症疫苗的用途
CA2796379A1 (en) Method for proliferation of antigen-specific t cells
JP2006020648A5 (enExample)
CN107109364A (zh) 缺氧与常氧交替条件下的骨髓浸润淋巴细胞的激活
CN101258238A (zh) 抗原呈递细胞的活化处理方法
AU2011291477B2 (en) Cells expressing Th1 characteristics and cytolytic properties
ZA200401842B (en) Process for the maturation of dentritic cells and a vaccine.
Luo et al. Human amniotic fluid stem cells suppress PBMC proliferation through IDO and IL-10-dependent pathways
Yannelli et al. The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC)
CN101313061A (zh) 扩增双阴性t细胞的方法
JP2012504948A5 (enExample)
MX2022006547A (es) Métodos para la expansión de poblaciones de células t gamma delta con agentes multivalentes y composiciones de estas.
Aloysius et al. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs
Moyer et al. Early vaccination with tumor lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects
Gel’m et al. Functional activity of lymphocytes of healthy donors and cancer patients after culturing with IL-2 and IL-15
Kuriyama et al. Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination
JP4111394B2 (ja) 改変標的化t細胞の製造方法及び医薬
Shao et al. Engineered cells for costimulatory enhancement combined with IL-21 enhance the generation of PD-1-disrupted CTLs for adoptive immunotherapy
JP6782503B1 (ja) 癌治療用細胞組成物を製造する方法、それにより製造される癌治療用細胞組成物、及び癌治療用細胞組成物を用いた癌の治療方法
Yan et al. Killing effect of interleukin-13 receptor alpha 2 (IL-13Rα2) sensitized DC–CTL cells on human glioblastoma U251 cells
Mohamed Adil et al. Role of mesenchymal cells and immunosuppressive cells within inflammatory tumor microenvironment
HK40084539A (en) Pepmixes to generate multiviral ctls with broad specificity
Sobh The Potential Role of Regulatory T Lymphocytes (Tregs) In Cancer